Amylyx Pharmaceuticals, Inc. (AMLX)
34.10
+0.14
(+0.41%)
USD |
NASDAQ |
Sep 04, 16:00
34.12
+0.02
(+0.07%)
After-Hours: 20:00
Amylyx Pharmaceuticals Research and Development Expense (Quarterly) : 23.72M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.72M |
| March 31, 2026 | 27.51M |
| December 31, 2025 | 21.10M |
| September 30, 2025 | 19.74M |
| June 30, 2025 | 27.08M |
| March 31, 2025 | 21.96M |
| December 31, 2024 | 22.73M |
| September 30, 2024 | 21.02M |
| June 30, 2024 | 23.14M |
| March 31, 2024 | 36.29M |
| December 31, 2023 | 44.61M |
| September 30, 2023 | 29.74M |
| Date | Value |
|---|---|
| June 30, 2023 | 28.76M |
| March 31, 2023 | 23.99M |
| December 31, 2022 | 22.81M |
| September 30, 2022 | 24.75M |
| June 30, 2022 | 24.15M |
| March 31, 2022 | 21.43M |
| December 31, 2021 | 13.39M |
| September 30, 2021 | 12.85M |
| June 30, 2021 | 10.92M |
| March 31, 2021 | 6.854M |
| December 31, 2020 | 5.013M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.746B |
| Eli Lilly & Co. | 3.819B |
| Merck & Co., Inc. | 9.229B |
| EyePoint, Inc. | 83.61M |
| Bristol Myers Squibb Co. | 2.316B |